# Whole-body MRI [Home](../README.md) · [Cancer and early detection](../WATCHLIST.md#cancer-early-detection) · [Calendar](../MILESTONES.md) Tags: [Screening and earlier detection](../BROWSE.md#screening) · [Devices and procedures](../BROWSE.md#devices-procedures) ## Current state A new review of heterogeneous screening cohorts estimates pathology-confirmed cancer yield but cannot establish improved patient outcomes. Downstream workups, false positives, overdiagnosis and the benefit of repeated screening remain unresolved. Status: active. Initial baseline reviewed September 12, 2026; focused review, not a systematic review. ## Questions to follow - Do large prospective studies or randomized trials show that regular whole-body MRI screening improves outcomes in asymptomatic people? - What do repeated rounds add compared with a single scan or usual care? What screening intervals have actually been tested? - Track mortality, advanced disease, treatment burden, quality of life, false positives, incidental findings, downstream procedures, overdiagnosis, and cost effectiveness where available. - Clearly separate average-risk screening from high-risk hereditary surveillance and imaging used to investigate symptoms. ## Programs and next milestones ### Focused update — 2026-10-16 No additional finding was selected from these checked sources. Coverage remains incomplete; this is not a full-topic “no news” conclusion. **Remaining gaps:** Focused update; current page and named HERCULES registry checked, and the first-posted discovery query completed after retry. Its two hits were treatment trials using MRI measurements, not population whole-body screening programs. October 1 systematic review and previously saved commercial podcast claims were deduplicated. Actual October 14 SABI presentation materials, all UK Biobank follow-up analyses and worldwide screening guidance were not comprehensively appraised. No comprehensive no-news conclusion; retain the older full successful-check timestamp. **Informal-source coverage:** Targeted indexed Reddit/podcast discovery did not supply a distinct attributable new development rumor. Commercial scan anecdotes and existing Durand/Prenuvo predictions were not converted into outcome evidence. Complete podcast audio and the October 14 SABI talks were not reviewed. [Full coverage record](../updates/2026-10-16_scheduled_research_update.md). ### Focused update — 2026-10-13 No additional finding was selected from these checked sources. Coverage remains incomplete; this is not a full-topic “no news” conclusion. **Remaining gaps:** Read current topic/state and shared notebook documents; searched September 5–October 13 overlap, including new publications and registry discovery. HERCULES live API remains recruiting in an April 2025 record, with no posted results; registry timing is unchanged old estimates.; New discovery matches were muscle imaging or diagnosed-disease assessment, not a qualifying repeated-screening outcome study. Reappraised saved October 1 JGIM review and October-issue Clinical Imaging commentary without duplicate event. SABI October 14 agenda includes general-public whole-body-MRI discussion, not an announced outcomes readout.; International registries, all downstream/repeated-round outcome literature and guidance changes remain incomplete. **Informal-source coverage:** Targeted Reddit and podcast searches reviewed original/indexed material. October 11 Scholar request is for a 2021 paper, not fresh outcomes; Levels 313/Durand original October 1 transcript remains opinion about future adoption, not proven screening health benefit. No distinct attributable new development rumor selected; full podcast census incomplete. [Full coverage record](../updates/2026-10-13_scheduled_research_update.md). ### Focused update — 2026-10-09 No additional finding was selected from the reviewed sources. Coverage remains incomplete; this is not a full-topic “no news” conclusion. **Remaining gaps:** Read current topic/state and September5 overlap; all named registry records retrieved using live CT.gov API. HERCULES remains recruiting in an April2025 record; no result posted and its future completion dates remain estimates.; Opened October1 Levels original episode313 full transcript; reappraised October1 JGIM review already saved October6, therefore no duplicate event. New discovery matches were diagnostic/prostate-treatment imaging or unrelated studies, not a qualifying repeated-screening outcome trial.; International registries, long-term outcomes and all imaging-policy changes remain incompletely searched. Prenuvo research-network enrollment statements are undated and were not treated as a dated new milestone. **Informal-source coverage:** Original Levels episode313, October1, DrDanielDurand/Prenuvo CMO with MikeHaney, full transcript now accessible. At52:35 and the corresponding transcript he predicts routine scans becoming commonplace; longitudinal-baseline benefits remain opinion/hypothesis, not new controlled outcomes. No distinct development rumor selected. Podcast census remains incomplete. [Full coverage record](../updates/2026-10-09_scheduled_research_update.md). ### Focused update — 2026-10-06 #### Whole-body MRI review quantifies findings and workups; patient benefit remains unknown **Source/event date:** October 1, 2026 publication; included studies were published 2005–2024. **Evidence:** Peer-reviewed systematic review, PROSPERO CRD42024554848. Seventeen heterogeneous, low-quality studies included 18,043 people without an evidence-based whole-body MRI indication. Cancer yield was **1.4% (95% CI 0.9–2.2%)**, based on **4,463** participants with pathologically confirmed reporting. Nonmalignant actionable findings occurred in **14.8% (6.6–30.0%)** of 17,167 participants. Among people with these findings, **58.2% (36.0–77.5%)** received further labs/imaging and **20.8% (9.7–39.2%)** underwent procedures; these are conditional percentages, not percentages of all screened people. **Limits and harms:** Diagnostic resolution and health outcomes were not reported well enough to calculate false positives or overdiagnosis or establish reduced mortality. Protocols, populations and outcome denominators differed; no race/ethnicity reporting. Detection yield is not proven clinical benefit. This is a new synthesis of older cohorts, not a new screening trial or HERCULES readout. **U.S. status / next milestone:** No new authorization or screening recommendation from this paper. Controlled prospective outcomes and repeated-round benefit/harm data remain needed; no announced readout date. [Full primary review](https://link.springer.com/article/10.1007/s11606-026-10802-y). **Coverage:** whole body MRI screening HERCULES results October 2026 September 2026; whole body MRI September 28 2026 Philip Lacy podcast HERCULES; "whole-body MRI" "October 2026" results screening study **Remaining gaps:** Read current topic/state, searched overlap from September 5 (last full success September 12), prioritizing changes missed at October 2 focused check.; Appraised October 1 JGIM systematic review full primary article, HERCULES official study site, and September 28 Andrew Lacy podcast indexed official show notes.; HERCULES live registry API inaccessible; existing April 2025 status/date snapshot not re-verified. No comprehensive international registry, repeated-round outcomes or full podcast/audio sweep. **Informal-source coverage:** Revisited September 28 mindbodygreen episode668, Andrew Lacy (Prenuvo CEO) with host Jason Wachob. Original show-note indexing specifies an internally derived 5% radiologically suspected potentially life-saving finding claim, not saved lives or mortality benefit; 200k scans is a commercial experience claim. Full page failed; audio unreviewed. October1 Levels #313 official indexed show notes also located, full page failed. No distinct new rumor selected. [Full coverage record](../updates/2026-10-06_scheduled_research_update.md). ### Focused update — 2026-10-02 No additional material finding was verified in this focused pass. Coverage remains incomplete; this is not a full-topic “no news” conclusion. **Coverage:** Whole-body MRI screening outcomes September October 2026 HERCULES; NCT06212479 current registry; whole body MRI screening Reddit September 2026. **Remaining gaps:** HERCULES registry unchanged since April 30 2025: recruiting, planned 100000, estimated January 2034 primary/January 2037 final, no results. No new large prospective screening outcomes identified in focused search. October Clinical Imaging commentary located; lung-cancer staging paper excluded as not average-risk screening. Full downstream-harm/outcome literature and Lacy podcast review remain incomplete. **Informal-source coverage:** No additional attributable signal selected in this focused search; Reddit mostly older commercial-scan experiences with newer comments. Existing September 28 podcast claim not fully reassessed. **Next update:** No reliable definitive-results publication date. HERCULES lists January 2034 primary completion and January 2037 study completion in its April 30, 2025 registry record; these are old registry estimates, not announced readouts. Incremental observational news in late 2026–2027 remains a low-confidence monitoring estimate. [Registry](https://clinicaltrials.gov/study/NCT06212479). [Full coverage record](../updates/2026-10-02_scheduled_research_update.md). ### Focused update — 2026-09-27 No additional finding was verified in the reviewed sources. Coverage remains partial; this is not a full-topic “no news” conclusion. **Coverage:** Searched September 5–27 human whole-body screening evidence, HERCULES and review publications. New AJR expert review is not a new screening-outcome trial. **Remaining gaps:** Full AJR review, registry history and downstream outcome papers were not completely appraised; no comprehensive international registry census. **Informal-source coverage:** Reddit and screening-discussion searches mainly found personal experience and commercial claims. No new attributable trial-result rumor selected; full podcast audio not reviewed. [Full coverage record](../updates/2026-09-27_scheduled_research_update.md). ### Focused update — 2026-09-22 No additional finding was verified in the reviewed sources. Coverage remains partial; this is not a full-topic “no news” conclusion. **Coverage:** Refreshed HERCULES original registry, searched September human screening-outcome reports and upcoming trials; no new outcome verified in reviewed sources. **Remaining gaps:** HERCULES retains April 2025 verification and no results; actual ongoing recruitment unverified. Cochrane item is an August review protocol, not outcome evidence. Full repeat-screening literature and all screening cohorts not reappraised. **Informal-source coverage:** Flex Diet episode405 September21 show notes and timestamp list checked; educational discussion, no new trial result or concrete new rumor. Full audio not reviewed. https://podcasts.apple.com/nz/podcast/episode-405-whole-body-mri-ct-scans-and-what-imaging/id1488376804?i=1000790902903 [Full coverage record](../updates/2026-09-22_scheduled_research_update.md). ### Focused update — 2026-09-18 No additional finding was verified in this focused search. The incomplete coverage below does not establish that nothing changed across the full topic. **Coverage:** HERCULES original registry and recent human screening-outcome discovery; unchanged stale April 2025 record, no new outcome verified. This is a focused review, not a complete re-review of every program. **Remaining gaps:** ACR/CAR and full repeat-screening literature not comprehensively reopened; 327-person older observational paper is not a new September outcome. **Informal-source coverage:** MRI/Galleri podcast and Reddit searches surfaced commercial prevention discussion (including secondhand Sept4 Hyman episode), not a specific new attributable trial-result rumor; full recordings not reviewed. [Full coverage record](../updates/2026-09-18_scheduled_research_update.md). **Next update:** No reliable definitive-results publication date. HERCULES lists January 2034 primary completion and January 2037 study completion in its April 30, 2025 registry record; these are old registry estimates, not announced readouts. Incremental observational news in late 2026–2027 remains a low-confidence monitoring estimate. [Registry](https://clinicaltrials.gov/study/NCT06212479). ### Tracked programs and current evidence The central unanswered question is whether repeated whole-body MRI screening improves patient outcomes in average-risk, asymptomatic adults. Large imaging datasets and detection studies exist, but this review found no completed large randomized trial establishing a mortality benefit. See the dated baseline below. ### Baseline evidence #### September 12, 2026 — initial baseline **Current assessment.** Regular whole-body MRI remains an unproven population-screening strategy. The American College of Radiology's current posted statement does not recommend it for people without symptoms, risk factors, or relevant family history because clinical benefit has not been demonstrated. The Canadian Association of Radiologists' June 2025 statement likewise finds no compelling high-quality evidence of improved morbidity or mortality. Both identify downstream investigations as a concern. This does not mean an individual scan cannot discover an important lesion; it means finding lesions has not established a favorable overall benefit-harm balance. [ACR statement](https://www.acr.org/News-and-Publications/Media-Center/2023/ACR-Statement-on-Screening-Total-Body-MRI); [CAR policy](https://car.ca/wp-content/uploads/2025/09/CAR-Policy-Statement-Whole-Body-MRI-Screening-in-Asymptomatic-Individuals.pdf). **HERCULES / Prenuvo — the relevant large prospective study.** [NCT06212479](https://clinicaltrials.gov/study/NCT06212479) targets up to 100,000 adults. The study site is soliciting enrollment, with follow-up calls 12–18 months after scanning. Its stated primary objective is prediction of clinically significant diagnoses. The 2025 ASCO trial-in-progress abstract describes diagnostic accuracy, stage, diagnostic pathways, utilization and cost-effectiveness, with self-funded and subsidized participant groups. It is a prospective real-world study; these payment groups are not randomized MRI-versus-no-MRI arms. No mature result establishing that repeated screening reduces deaths was located. [Study site](https://www.herculesstudy.org/); [investigator ASCO abstract, May 28, 2025](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS10626). **UK Biobank — large scale, different question.** The imaging project has scanned 100,000 participants and is inviting up to 60,000 for repeat imaging 2–7 years later. These data can reveal disease associations, prediction, and changes with aging. They do not themselves test whether offering routine commercial screening improves outcomes versus usual care. [UK Biobank imaging project](https://www.ukbiobank.ac.uk/taking-part/participant-opportunities/imaging-project/). **New evidence-review work.** A Cochrane protocol published August 25, 2026 proposes to evaluate benefits and harms of whole-body MRI/CT screening. It is a review protocol, not a completed evidence synthesis or positive trial readout. [Protocol / PMID 42639816](https://pubmed.ncbi.nlm.nih.gov/42639816/). **Expected next update.** No reliable date for a definitive screening-outcomes answer was identified. An incremental observational or conference update during late 2026–2027 is a low-confidence monitoring estimate, not an announced HERCULES readout. The decisive event to watch is a controlled long-term outcome comparison, with harms and repeat-screening intervals measured. **Coverage limits.** Trial-registry detail pages/API did not render reliably in this check; HERCULES design and current enrollment invitation are grounded in its study site and the primary investigator abstract. No current registry completion date is asserted. This baseline concerns average-risk asymptomatic screening, not hereditary high-risk surveillance. ## Dated history ### 2026-10-02 — Scheduled focused review 0 newly recorded findings or milestones; primary evidence, uncertainty and incomplete coverage are detailed above and in the [run record](../updates/2026-10-02_scheduled_research_update.md). Full-topic successful-check dates remain unchanged. - **2026-09-27:** 0 sourced entries and 0 cross-topic links from a focused scheduled check. [Coverage and remaining gaps](../updates/2026-09-27_scheduled_research_update.md). - **2026-09-22:** Focused scheduled research retry; 0 sourced entries and 0 cross-topic links. [Coverage and gaps](../updates/2026-09-22_scheduled_research_update.md). ### 2026-09-14 — Focused ad-hoc update **Result and provenance:** The [HERCULES study site](https://www.herculesstudy.org/) continues to invite enrollment. The [registry record](https://clinicaltrials.gov/study/NCT06212479), retrieved through its public API, lists recruiting, a target of 100,000, estimated primary completion in January 2034 and study completion in January 2037. Its last posted update is April 30, 2025, so these dates close an earlier access gap rather than constitute a new September development. Recruitment status can lag actual conduct. No controlled outcome result demonstrating benefit from average-risk whole-body MRI screening was located in the checked sources. **Coverage:** Focused study-site, registry and recent outcome/harms discovery searches, plus informal discussion searches. Commercial explainers and personal screening experiences were not promoted as clinical evidence. UK Biobank, professional-society guidance and the full imaging literature were not comprehensively refreshed; this is a partial check, not an exhaustive no-news conclusion. ### Dated findings The dated baseline entries are preserved under [Baseline evidence](#baseline-evidence). ### 2026-09-18 — Scheduled focused review HERCULES original registry and recent human screening-outcome discovery; unchanged stale April 2025 record, no new outcome verified. Original event dates, safety and limitations are retained in the September 18 update above. The complete-topic successful-check date was not advanced because the listed gaps remain. [Run record](../updates/2026-09-18_scheduled_research_update.md).